2S,4S,5S-6-Cyclohexyl-5-(t-butoxycarbonylamino)-2-(2-methylpropyl)gamma-hexanolactone | 112227-11-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: 2S,4S,5S-6-Cyclohexyl-5-(t-butoxycarbonylamino)-2-(2-methylpropyl)gamma-hexanolactone
• 英文别名: tert-butyl N-[(1S)-2-cyclohexyl-1-[(2S,4S)-4-(2-methylpropyl)-5-oxooxolan-2-yl]ethyl]carbamate
• CAS: 112227-11-9
• 化学式: C₂₁H₃₇NO₄
• 分子量: 367.529
• InChiKey: WWZSFAIZKXCSKS-BZSNNMDCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2S,4S,5S-6-Cyclohexyl-5-(t-butoxycarbonylamino)-2-(2-methylpropyl)gamma-hexanolactone 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 (3S,5S)-5-((S)-1-Amino-2-cyclohexyl-ethyl)-3-isobutyl-dihydro-furan-2-one
  参考文献：
  名称：

  The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template

  摘要：

  The present manuscript details the discovery and early fundamental structure-activity relationship studies, involving compound 3, a novel hydroxyethylene peptide isostere derived molecule that provides micromolar inhibition of CCL3 binding to its receptor CCR1. Initial studies established this screening hit as a legitimate lead for further medicinal chemistry optimization. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.020
• 作为产物：
  描述：

  (5S)-5-[(1S)-1-(N-t-butoxycarbonylamino)-2-cyclohexylethyl]dihydrofuran-2(3H)-one 在 palladium on activated charcoal 氢气 、 lithium hexamethyldisilazane 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 2S,4S,5S-6-Cyclohexyl-5-(t-butoxycarbonylamino)-2-(2-methylpropyl)gamma-hexanolactone
  参考文献：
  名称：

  The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template

  摘要：

  The present manuscript details the discovery and early fundamental structure-activity relationship studies, involving compound 3, a novel hydroxyethylene peptide isostere derived molecule that provides micromolar inhibition of CCL3 binding to its receptor CCR1. Initial studies established this screening hit as a legitimate lead for further medicinal chemistry optimization. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.020

文献信息

• US4729985
  申请人：——

  公开号：——

  公开（公告）日：——
• Polypeptide derivatives containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues
  申请人：PFIZER INC.

  公开号：EP0212903B1

  公开（公告）日：1992-12-30
• US4729985A
  申请人：——

  公开号：US4729985A

  公开（公告）日：1988-03-08
• US4948913A
  申请人：——

  公开号：US4948913A

  公开（公告）日：1990-08-14
• The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template
  作者：John C Kath、Amy P DiRico、Ronald P Gladue、William H Martin、Eric B McElroy、Ingrid A Stock、Laurie A Tylaska、Deye Zheng

  DOI：10.1016/j.bmcl.2004.02.020

  日期：2004.5

  The present manuscript details the discovery and early fundamental structure-activity relationship studies, involving compound 3, a novel hydroxyethylene peptide isostere derived molecule that provides micromolar inhibition of CCL3 binding to its receptor CCR1. Initial studies established this screening hit as a legitimate lead for further medicinal chemistry optimization. (C) 2004 Elsevier Ltd. All rights reserved.